ADCT ADC Therapeutics SA
Pharmaceutical Preparations · NYSE · SEC CIK 1771910 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.8%
TTM net income YoY51.3%
TTM EPS YoY67.4%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-97.7%
Net margin-95.7%
FCF margin-118.5%
EBITDA margin—
Returns
ROE—
ROA-29.8%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets197.4%
Debt / equity—
Current ratio3.05x
Interest coverage-1.58x
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $81.36M | $70.84M | $69.56M | $209.91M | $33.92M |
| Cost of revenue | $5.80M | $5.95M | $2.53M | $3.30M | $1.39M |
| Gross profit | $75.56M | $64.89M | $67.03M | $206.61M | $32.52M |
| R&D expense | $104.00M | $109.63M | $127.13M | $186.46M | $158.00M |
| SG&A expense | $36.56M | $41.89M | $48.42M | $74.44M | $71.46M |
| Operating income | -$121.50M | -$130.65M | -$165.99M | -$123.34M | -$261.72M |
| Interest expense | $51.63M | $50.21M | $46.33M | $36.73M | $18.34M |
| Pretax income | -$141.61M | -$156.14M | -$195.42M | -$146.82M | -$251.50M |
| Income tax | $1.01M | $166,000 | $39.11M | $227,000 | -$21.48M |
| Net income | -$142.62M | -$157.85M | -$240.05M | -$157.13M | -$230.03M |
| EBITDA | -$120.79M | -$129.32M | -$164.80M | -$122.28M | — |
| EPS (basic) | -1.12 | -1.62 | -2.94 | -2.01 | — |
| EPS (diluted) | -1.12 | -1.62 | -2.94 | -2.01 | — |
| Weighted avg. shares (diluted) | 127.07M | 97.16M | 81.71M | 78.15M | — |
| Balance sheet | |||||
| Cash & equivalents | $261.34M | $250.87M | $278.60M | $326.44M | $466.54M |
| Receivables | — | — | — | $72.97M | $30.22M |
| Inventory | $4.18M | $2.25M | $16.18M | $12.07M | $11.12M |
| Current assets | $306.33M | $291.25M | $336.29M | $434.98M | $525.18M |
| PP&E, net | $0 | $5.08M | $5.62M | $3.35M | $4.07M |
| Intangibles | — | — | — | $14.36M | $13.58M |
| Total assets | $323.15M | $321.98M | $354.78M | $490.86M | $617.97M |
| Current liabilities | $70.16M | $80.47M | $67.67M | $81.94M | $73.94M |
| Short-term debt | $3.00M | $0 | — | $12.47M | $6.58M |
| Long-term debt | — | — | — | — | $87.15M |
| Total debt | — | — | — | — | $93.73M |
| Total liabilities | $508.98M | $524.62M | $503.03M | $411.41M | $451.88M |
| Shareholders' equity | -$185.83M | -$202.64M | -$148.25M | $79.45M | $154.03M |
| Net debt | — | — | — | — | -$372.82M |
| Shares outstanding | 125.75M | 98.86M | 82.29M | 80.64M | — |
| Cash flow statement | |||||
| Operating cash flow | -$141.17M | -$123.83M | -$118.69M | -$138.31M | -$233.38M |
| Capital expenditure | $264,000 | $867,000 | $3.22M | $687,000 | $3.43M |
| Free cash flow | -$141.44M | -$124.70M | -$121.90M | -$139.00M | -$236.81M |
| Investing cash flow | $395,000 | -$867,000 | -$3.22M | -$687,000 | -$6.67M |
| Financing cash flow | $150.94M | $97.05M | $73.88M | -$897,000 | $267.39M |
| Depreciation & amortization | $705,000 | $1.33M | $1.19M | $1.06M | — |
| Stock-based compensation | $6.91M | $6.57M | $13.49M | $49.32M | $60.48M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.